Literature DB >> 9461189

A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen.

G Wang1, R K Chopra, R E Royal, J C Yang, S A Rosenberg, P Hwu.   

Abstract

In order to treat common cancers with immunotherapy, chimeric receptors have been developed that combine the tumor specificity of antibodies with T-cell effector functions. Previously, we demonstrated that T cells transduced with a chimeric receptor gene against human ovarian cancer were able to recognize ovarian cancer cells in vitro and in vivo. We now report that recipients of bone marrow cells transduced with these genes exhibited significant antitumor activity in vivo. Moreover, in vivo depletion of T cells in reconstituted mice did not affect antitumor activity, suggesting that other immune cells expressing the chimeric receptor gene may play an important role in tumor rejection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9461189     DOI: 10.1038/nm0298-168

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  11 in total

Review 1.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

2.  Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.

Authors:  Alena A Chekmasova; Thapi D Rao; Yan Nikhamin; Kay J Park; Douglas A Levine; David R Spriggs; Renier J Brentjens
Journal:  Clin Cancer Res       Date:  2010-07-13       Impact factor: 12.531

Review 3.  Potential applications of gene therapy in the patient with cancer.

Authors:  P W Szlosarek; A G Dalgleish
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

4.  Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.

Authors:  Nehad M Alajez; Jan Schmielau; Mark D Alter; Michael Cascio; Olivera J Finn
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

Review 5.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

Review 6.  Immunotherapy of human cancers using gene modified T lymphocytes.

Authors:  Juan F Vera; Malcolm K Brenner; Gianpietro Dotti
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

Review 7.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

8.  Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.

Authors:  Z K Klippel; J Chou; A M Towlerton; L N Voong; P Robbins; W I Bensinger; E H Warren
Journal:  Gene Ther       Date:  2014-01-23       Impact factor: 5.250

Review 9.  Clinical application of genetically modified T cells in cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Clare Y Slaney; Phillip K Darcy
Journal:  Clin Transl Immunology       Date:  2014-05-16

10.  Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.

Authors:  John Maher
Journal:  ISRN Oncol       Date:  2012-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.